Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Markets

Trump’s Tariff Threats Target Big Pharma, But Tax Reforms May Hold the Key to U.S. Manufacturing Growth

by Team Lumida
May 7, 2025
in Markets
Reading Time: 5 mins read
A A
0
Fed Official Warns of Inflation Risks Under Trump Presidency

"Donald Trump" by Gage Skidmore is licensed under CC BY-SA 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • President Trump’s proposed tariffs on the pharmaceutical industry aim to bring more drug production back to the U.S., but experts argue that tax reforms could be a more effective long-term solution.
  • Pharma companies historically moved offshore not for cheap labor but to benefit from lower corporate tax rates in countries like Ireland, which offered a 12.5% rate compared to the U.S.’s pre-2017 rate of 35%.
  • Trump’s 2017 tax reforms, which lowered the U.S. corporate tax rate to 21% and introduced a minimum tax on foreign earnings, have already made U.S. production more attractive.
  • Industry leaders, including CEOs from Eli Lilly, Pfizer, and Johnson & Johnson, are pushing for further tax incentives, such as a 15% tax rate for U.S. manufacturing, restored R&D deductions, and more favorable interest deductions for domestic facility investments.
  • Generic drug production, which has largely shifted to India and China, poses a unique challenge due to its low margins. Tariffs on generics could worsen drug shortages and quality issues in the U.S.

What Happened?

President Trump’s administration is ramping up pressure on the pharmaceutical industry with proposed tariffs aimed at reshoring drug production. While tariffs have prompted some companies to expand U.S. operations, experts argue that tax reforms would be a more sustainable way to encourage long-term investment.

Pharma companies have historically moved operations offshore to benefit from lower tax rates, not cheaper labor. Trump’s 2017 tax reforms reduced the corporate tax rate and introduced measures like the Global Intangible Low-Taxed Income (GILTI) regime, which taxed foreign earnings. However, loopholes still allow companies to report U.S.-generated profits in low-tax jurisdictions.

Congress is now considering additional tax incentives, such as a 15% tax rate for U.S. manufacturing and restored R&D deductions, to further boost domestic production. At the same time, policymakers are exploring ways to tighten GILTI rules to ensure they apply only to genuinely foreign profits.


Why It Matters?

The pharmaceutical industry is one of the few sectors where reshoring is feasible due to its high margins and reliance on intellectual property rather than cheap labor. However, tariffs alone may not be enough to drive meaningful change.

Tax reforms, such as lowering the tax rate for U.S. manufacturing and restoring R&D incentives, could provide a more effective and sustainable framework for reshoring. These measures would not only encourage investment but also ensure that profits are reported and taxed in the U.S.

For generic drug production, which has largely moved to India and China, tariffs could exacerbate existing issues like drug shortages and quality concerns. Direct financial support from the government may be necessary to bring portions of this industry back to the U.S.


What’s Next?

Pharma companies have already announced significant U.S. investments, with Eli Lilly, Roche, and Johnson & Johnson pledging a combined $132 billion to expand domestic operations. However, the sustainability of these investments will depend on whether Congress enacts further tax reforms.

Policymakers will also need to address the unique challenges of the generic drug industry, potentially through targeted financial support or incentives. The outcome of these efforts will shape the future of U.S. pharmaceutical manufacturing and its ability to compete globally.

Source
Previous Post

SEC Delays Decision on Litecoin ETF, Requests Public Comments

Next Post

Mark Zuckerberg Envisions a Future Where AI Friends Outnumber Human Companions

Recommended For You

Apple Guides a Big Holiday Quarter on iPhone 17 Upgrades; Services Top $100B

by Team Lumida
15 hours ago
Apple Guides a Big Holiday Quarter on iPhone 17 Upgrades; Services Top $100B

Key Takeaways Powered by lumidawealth.com September-quarter revenue $102.5B (+8% YoY) and shares +~3% after-hours. December-quarter guide: total revenue +10% to +12% YoY, led by double-digit iPhone growth. iPhone revenue...

Read more

Big Tech’s AI Capex Hits $78B in a Quarter, Testing Market Patience

by Team Lumida
2 days ago
a black square with a blue logo on it

Key Takeaways Powered by lumidawealth.com Alphabet, Meta, and Microsoft spent ~$78B on capex last quarter, +89% YoY, mostly for AI data centers and GPUs. Stocks split: Meta and Microsoft...

Read more

Tesla’s Cybercab Backup Plan: Sell It With a Steering Wheel

by Team Lumida
3 days ago
a car's speedometer with red lights

Key Takeaways Tesla board chair Robyn Denholm said Cybercab (long-promised affordable EV) can have steering wheel/pedals if needed—crucial wiggle room vs. Musk's "pointless" $25K regular model comment a...

Read more

Amazon to Lay Off Up to 30,000 Corporate Workers

by Team Lumida
4 days ago
Amazon’s $100 Billion Bet: AI Over Retail

Key Takeaways Powered by lumidawealth.com Amazon cutting up to 30,000 corporate employees (~10% of white-collar workforce) starting Tuesday, largest layoffs since 27,000 eliminated in 2022; hits HR, AWS, advertising,...

Read more

Gold Trading Talent War Heats Up as Bullion Boom Drives Hiring and Pay Surges

by Team Lumida
5 days ago
gold and black metal tool

Key Takeaways Powered by lumidawealth.com Major trading houses (Trafigura, Gunvor, IXM, Mercuria) and hedge funds are aggressively hiring gold traders amid soaring market activity. Banks historically dominated gold trading...

Read more

Microsoft Faces Legal Action in Australia Over Copilot Pricing Practices

by Team Lumida
5 days ago
The AI Investment Dilemma: Future-Proof or Financial Folly?

Key Takeaways Australia’s ACCC has sued Microsoft for allegedly misleading 2.7M Microsoft 365 subscribers on Copilot-related price hikes. Regulator claims Microsoft hid cheaper “classic” non-Copilot plans until users...

Read more

Wall Street Prices Optionality on Trump Tariffs Ahead of Supreme Court Ruling

by Team Lumida
7 days ago
Wall Street Prices Optionality on Trump Tariffs Ahead of Supreme Court Ruling

Key Takeaways Powered by lumidawealth.com Banks are brokering claims trades where importers sell future tariff-refund rights at a discount; hedge funds take legal risk for potential multi-bagger payouts. Typical...

Read more

Meta Charged by EU Over Handling of Illegal Content

by Team Lumida
1 week ago
a black square with a blue logo on it

Key Takeaways Powered by lumidawealth.com EU Commission charged Meta under Digital Services Act (DSA) for failing to provide simple illegal-content flagging and adequate appeal tools for content-moderation decisions on...

Read more

Trump Administration in Talks to Take Equity Stakes in Quantum-Computing Firms

by Team Lumida
1 week ago
Trump Administration in Talks to Take Equity Stakes in Quantum-Computing Firms

Key Takeaways Powered by lumidawealth.com Commerce Dept. negotiating equity stakes in quantum firms (IonQ, Rigetti, D-Wave, QCI, Atom Computing) in exchange for federal funding; minimum awards ~$10M each from...

Read more

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue

by Team Lumida
1 week ago
Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue

Key Takeaways Powered by lumidawealth.com Guidance raised: core EPS now high single-digit to low double-digit growth at CER (from high single-digit); full-year sales still mid-single-digit growth ex-FX. Q3 miss...

Read more
Next Post
a white square with a blue logo on it

Mark Zuckerberg Envisions a Future Where AI Friends Outnumber Human Companions

China’s Bold Economic Moves: What You Need to Know Now

China Cuts Rates and Injects $139 Billion in Liquidity to Counter U.S. Tariffs

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Axon Enterprise Earnings Highlights: Record Q2 Revenue Exceeds $500 Million

Axon Enterprise Earnings Highlights: Record Q2 Revenue Exceeds $500 Million

August 7, 2024
white and black abstract illustration

US Household Wealth Surges to Record $160 Trillion – What’s Driving It?

June 10, 2024
Trump Delays Reciprocal Tariffs to August 1, Citing Progress in Trade Negotiations

Trump Delays Reciprocal Tariffs to August 1, Citing Progress in Trade Negotiations

July 9, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018